#USA #Middleton #BioLab Holdings #Imbed Biosciences #SAM Technology

Imbed Biosciences Secures Strategic Investment from BioLab Holdings

Imbed Biosciences, recognized for its pioneering synthetic antimicrobial solutions and tissue regeneration techniques, has recently announced a vital strategic investment from BioLab Holdings Inc. This partnership is expected to significantly widen the reach of Imbed's technologies in the U.S. market, particularly within medical office settings, thereby accelerating the innovation of its proprietary SAM™ Antimicrobial Technology platform designed to reduce complications in wound care.

Terry Bromley, the CEO of Imbed Biosciences, stated, "The investment from BioLab Holdings is a watershed moment for us. It will greatly extend our footprint in the critical U.S. market, especially in physician office settings, and allow us to push forward with advancements in our unique technology platform, which integrates multiple therapeutic agents into a single product solution to address unmet needs in wound management."

Advancing Patient Care Solutions

The investment from BioLab Holdings empowers Imbed Biosciences to expand its innovative product lineup, which aims for a zero-complication goal in wound care. Supported by increasing clinical evidence, Imbed has carved out a niche in the skin substitute market by offering the only fully synthetic and antimicrobial solution available today. The funding primarily emphasizes enhancements to Imbed’s Microlyte® product, which is aimed at chronic wound treatments and designed to effectively reduce bioburden while promoting cellular growth during the vital scaffolding phase of healing.

Jaime Leija, president and CEO of BioLab Holdings, expressed enthusiasm regarding the investment: "At BioLab, we focus on platforms that can transform how clinicians approach wound care. Imbed's SAM™ technology exemplifies a blend of scientific rigor, practical design, and robust scalability. We perceive immense potential in facilitating its adoption within physician offices, all the while accelerating solutions that simplify care delivery and ultimately enhance patient outcomes."

The collaboration demonstrates a mutual dedication to advancing patient care in wound management through innovative and effective solutions. Interested parties are encouraged to review BioLab Holdings Inc.'s press release for further details.

About Imbed Biosciences

Imbed Biosciences operates as a privately held medical device enterprise focused on enhancing wound care through its groundbreaking SAM™ Antimicrobial Technology. This advanced platform incorporates various therapeutic agents within ultra-thin, biocompatible matrices to facilitate skin regeneration in various wound types, both chronic and acute. Imbed's growing portfolio is specifically crafted to reduce infection risks, alleviate discomfort, and foster healing across the entire spectrum of wound care.

About BioLab Holdings, Inc.

Based in Phoenix, BioLab Holdings, Inc. specializes in wound protection manufacturing. The company's innovative products, such as Membrane Wrap - Lite ™ and Membrane Wrap ™, utilize human tissue allografts derived from amniotic membranes to provide structural integrity for wounds. BioLab is committed to enhancing the standard of care through scientific innovations, compassion, and collaboration, ensuring improved outcomes for patients requiring wound care.

For further information on Imbed Biosciences and the potential of its advanced wound care technologies, visit Imbed Biosciences.